Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Shelley Amster
AddedMar 31, 2024
UpdatedMay 31, 2026
Shelley Amster

Shelley Amster

Board Member, Nephrogen

LinkedIn

Shelley Amster's Career

Nephrogen
Nephrogen

New York City, NY, US

Board Member· Board
3Daughters
3Daughters

Boston, MA, US

Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Shelley Amster's Career

Nephrogen
Nephrogen
Seed$150k12020New York City, NY, US
Board Member· Board

Recent news

And the winner of Startup Battlefield at Disrupt 2025 is: GlīdTechCrunch · 2025
Here are the 5 Startup Battlefield finalists at TechCrunch Disrupt 2025TechCrunch · 2025
Biotech Nephrogen combines AI and gene therapy to reverse kidney disease — check it out at TechCrunch Disrupt 2025TechCrunch · 2025

Leadership at Nephrogen

Demetri MaximDemetri MaximFounder
3Daughters
3Daughters
Seed$3M22021Boston, MA, US
Founder

Similar to 3Daughters

Rinovum Women's HealthRinovum Women's HealthMonroeville, PA, USMedical Devicesest. 2014Rinovum Women's HealthMonroeville, PA, US · est. 2014

Rinovum Womens Health LLC develops and manufactures at-home natural conception aids.

Series C · $29.7M30
Ceek Women's HealthCeek Women's HealthPortland, OR, USMedical Devicesest. 2015Ceek Women's HealthPortland, OR, US · est. 2015

Ceek Women's Health: Innovating gynecological care through advanced medical devices.

Series A · $4.7M30
BioceptiveBioceptiveNew Orleans, LA, USMedical Devicesest. 2010BioceptiveNew Orleans, LA, US · est. 2010

Bioceptive: Innovating women's health with a simplified intrauterine device inserter.

Angel · $3.2M6
PrivyPrivyAliso Viejo, CA, USFeminine Care, Health Productsest. 2014PrivyAliso Viejo, CA, US · est. 2014

California-based Privy offers clinically proven solutions for women's health issues, including UTIs and yeast infections.

Angel · $3.3M13

Shelley Amster's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Shelley Amster

Sonya BrownSonya BrownBoard Member · Harvard Business SchoolSteffan BerelowitzSteffan BerelowitzCo-Founder · BluetrainDebby MeredithDebby MeredithBoard Member · TaoWeaveBobby McDonaldBobby McDonaldCo-Founder · AmstatzKaren BlasingKaren BlasingBoard Member · GitLabShantur TaparShantur TaparCo-Founder · SaaS Industries